Concepedia

Author

Aliénor Berges

GlaxoSmithKline (United Kingdom)

Also Known As

A Berges, A. Berges, Alienor Berges, Alienor Berges (565979), Alienor C Berges, Alienor C. Berges, Aliénor Berges

49

Publications

1.2K

Citations

15

H-Index

28

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)AstraZeneca (United Kingdom)GlaxoSmithKline (United States)BioPharm (United Kingdom)AstraZeneca (Singapore)
AB

About

Aliénor Berges is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

160

2

Immunology

2

2

45

3

Biochemistry

1

1

13

4

Biomedical Engineering

1

1

33

5

Neurology

1

1

13

Aliénor Berges

×

16

Publications

1.1K

Citations

14

H-Index

YearCitations

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

Duncan Richards, Louise Cookson, Aliénor Berges,

New England Journal of Medicine

2015

364

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay,

Clinical Cancer Research

2021

125

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Richard Grove, Conn Harrington, Andreas Mahler,

Current Alzheimer Research

2014

108

Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

Vincent Meininger, Pierre-François Pradat, Andrea M. Corse,

PLoS ONE

2014

86

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Seung Tae Kim, Simon A. Smith, Peter G. Mortimer,

Clinical Cancer Research

2021

78

The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation

Pradeep J. Nathan, Rebecca Boardley, Nicola Scott,

Current Alzheimer Research

2013

68

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Timothy A. Yap, Matthew Krebs, S. Postel-Vinay,

European Journal of Cancer

2016

48

Unexpectedly high affinity of a novel histamine<scp>H<sub>3</sub></scp>receptor antagonist,<scp>GSK239512</scp>,<i>in vivo</i>in human brain, determined using<scp>PET</scp>

Sharon Ashworth, Aliénor Berges, Eugenii A. Rabiner,

British Journal of Pharmacology

2013

39

Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers

Matthew Krebs, Juanita Lopez, Anthony B. El-Khoueiry,

Cancer Research

2018

34

Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats

Armin Sepp, Guy Meno‐Tetang, Andrew Weber,

Journal of Pharmacokinetics and Pharmacodynamics

2019

33

Page 1